Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size

Zhao, Xin; Dai, Xiaojun; Wang, Shanshan; Yang, Ting; Yan, Yan; Guang, Zhu; Feng, Jun; Pan, Bo; Sunagawa, Makoto; Zhang, Xiaochun; Qian, Yayun; Liu, Yanqing

doi:10.1155/2018/4369027

Cited by 24 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be one of the most resultful strategies to improve the efficacy of prevention and treatment of lung cancer recurrence and metastasis. Although studies have shown that patients treated with TCM have a higher risk of death [ 21 ], several studies have recently verified that adjuvant CHM treatments are beneficial to cancer patients' disease control [ 22 – 26 ]. The above studies showed that adjuvant CHM treatments not only has a positive effect on the survival time of patients, but also reduces the risk of recurrence and metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…However, there might be no significant difference in survival for elderly patients with advanced EGFR wild-type NSCLC who accepted CHM treatment. CHM has shown numerous benefits for the treatment of lung cancer including preventing recurrence and metastasis [ 27 ], reducing toxicity when taken in combination with chemotherapy as well as alleviating leucopenia [ 12 , 22 , 26 ], enhancing therapeutic effect in non-small cell lung cancer patients harboring EGFR mutations and improving quality of life [ 26 , 28 ]. In addition, CHM could contribute to the recovery of immune function and improve TCM syndromes after operation [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy of Long-Term Chinese Herbal Medicine Use on Lung Cancer Survival Time: A Retrospective Two-Center Cohort Study with Propensity Score Matching

Zhang

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the efficacy of long-term use of Chinese herbal medicine (CHM) on survival time of lung cancer. Methods. We conducted a retrospective cohort study on lung cancer patients. A propensity score matching (PSM) was performed to balance the covariates. Progression-free survival (PFS) was the primary endpoint and overall survival (OS) was the secondary endpoint. Patients who received CHM therapy from the initial date of diagnosis of lung cancer were included in the CHM group. Patients who were not treated with CHM during the same interval were categorized in the control group. A Cox regression model was used to explore the prognostic factors related to lung cancer. Hazard ratios of different subgroups were also analyzed. Results. A total of 1134 patients were included in our study: 761 patients were in the CHM group and 373 patients were in the control group. After PSM, the mPFS and mOS in the CHM group were 70.4 months and 129.1 months, respectively, while the mPFS and mOS in the control group were 23.8 months and 99.7 months, respectively. The results of survival analysis on each stage demonstrated that patients may benefit from the long-term CHM treatment especially for patients with early stage. One-year to ten-year progression-free survival rates in the CHM group were higher than those in the control group ( p < 0.001 ). COX multivariate regression analysis indicated that CHM treatment, female, low age at diagnosis, early tumor stage, and surgery were independent protective factors against recurrence and metastasis of lung cancer. Subgroup analysis showed that CHM treatment could reduce the risk of recurrence and metastasis in each subgroup ( p < 0.01 ). Conclusion. Long-term CHM treatment with the Fuzheng Quxie Formula, which can be flexibly applied in the course of lung cancer treatment, not only has a positive influence on the progression-free survival time of lung cancer patients, but also reduces the risk of recurrence and metastasis of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Efficacy of Long-Term Chinese Herbal Medicine Use on Lung Cancer Survival Time: A Retrospective Two-Center Cohort Study with Propensity Score Matching

Zhang

Wang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…[ 26 ] CHM as an adjunctive therapy has shown obvious advantages in improving the clinical symptoms and the therapeutic efficacy of chemotherapy, as well as in alleviating the side effects of chemotherapy. [ 27 – 29 ] A systematic review published as early as 2012 showed that compared with chemotherapy alone, CHM, as an adjuvant therapy of chemotherapy, has significant efficacy in prolonging survival time, enhancing tumor response, improving QOL, regulating immune function and alleviating acute adverse reactions. [ 30 ] In recent years, it is common to use CHM combined with chemotherapy to treat CRC in China, but there are still few published systematic reviews in English, which has hindered the worldwide popularity of CHM.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer

Guo

Wang

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is a public health problem and the world's leading cancer killer. It is a disease with high incidence and mortality. Although chemotherapy has achieved some success in the treatment of CRC, drug resistance and tumor metastasis caused by chemotherapy are still the main causes of death in patients with CRC. Notably, many side effects associated with chemotherapy, such as nausea, vomiting, and peripheral neurotoxicity, are major challenges in the treatment of patients with CRC. Chinese herbal medicine (CHM) has been widely used as an adjunctive therapy for CRC, but its efficacy and safety are still uncertain. The aim of this systematic review is to assess the efficacy and safety of CHM for the treatment of CRC. Methods: A comprehensive retrieval will be performed in the following electronic databases: PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, SinoMed, VIP, and Wan Fang Data. The methodologic quality of randomized controlled trials will be assessed using the Cochrane risk assessment tool. Review Manager 5.3 software will be used for data synthesis and analysis. Funnel plot analysis and Egger test will be used to assess publication bias. The Grading of Recommendations Assessment, Development and Evaluation standard will be used to generate summary of finding table. Results: The results of this systematic review will be used to summarize and evaluate the evidence from randomized controlled clinical trials of CHM as adjuvant therapy for CRC. Conclusion: This review will provide a detailed summary of the evidence to assess the efficacy and safety of CHM for CRC. OSF Registration: DOI 10.17605/OSF.IO/X2SKJ

show abstract

“…A retrospective small-sample study was performed in patients with stage II~IIIA NSCLC. It was revealed that compared with the patients receiving ACT alone, those receiving Chinese medicine + ACT enjoyed a longer time without relapse or metastasis [10]. Our previous study showed that Chinese herbal medicines based on syndrome differentiation were able to improve the symptoms, including nausea, fatigue, pain and dry mouth, and also alleviate some chemotherapy-related side effects [11,12].…”

Section: (Continued From Previous Page)mentioning

confidence: 99%

Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

et al. 2020

View full text Add to dashboard Cite

Background: The toxicity and side effects caused by adjuvant chemotherapy (ACT) after radical surgery for lung adenocarcinoma (LAC) lead to early termination frequently. This study was conducted to provide an objective basis for the effect of Chinese herbal medicine formulas (CHMFs) combined with chemotherapy in reducing toxicity and enhancing efficacy of ACT.Method: From February 17th, 2012 to March 20th, 2015, 233 patients from 7 hospitals diagnosed with LAC in IB~IIIA stage were randomly assigned into ACT + CHMF group (116 patients) and ACT + placebo group (117 patients). CHMF was taken orally until the end of chemotherapy. Chemotherapy-related toxic, side effects were investigated as the primary outcome. Disease-free survival (DFS) and overall survival (OS) were used as the secondary outcome.Results: At one week following chemotherapy, the incidence of dry mouth, diarrhea and thrombocytopenia significantly decreased in CHMF group (P = 0.017, P = 0.033, P = 0.019, respectively). At two weeks following chemotherapy, fatigue and diarrhea were more obvious in the placebo group (P = 0.028, P = 0.025, respectively). In addition, patients in the CHMF group showed an increase in median DFS from 37.1 to 51.5 months compared with placebo group although there was no statistical significance (P = 0.16). In the stage IB subgroup, the CHMF group had a significantly better DFS (HR (95% CI) = 0.53 (0.28-0.99), P = 0.046). There was no significant difference in OS between the groups (P = 0.72). Conclusion: For patients with LAC, ACT combined with CHMF after radical surgery can prolong the DFS time especially in the early stage, and reduces the chemotherapy-related toxic and side effects.

show abstract

Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size

Cited by 24 publications

References 19 publications

The Efficacy of Long-Term Chinese Herbal Medicine Use on Lung Cancer Survival Time: A Retrospective Two-Center Cohort Study with Propensity Score Matching

The Efficacy of Long-Term Chinese Herbal Medicine Use on Lung Cancer Survival Time: A Retrospective Two-Center Cohort Study with Propensity Score Matching

The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer

Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Contact Info

Product

Resources

About